Drug firm Zydus Cadila on Monday said it has sought approval from the domestic drug regulator Drugs Controller General of India for additional indication of its hepatitis drug Pegylated Interferon Alpha-2b for treating COVID-19. Phase-III clinical trials with Pegylated Interferon Alpha 2b, which company sells under the brand name 'PegiHep' has shown promising results in treating COVID-19, Zydus Cadila said …
Zydus Cadila on Monday said it had sought approval from the Drugs Controller General of India for use of its viral hepatitis drug in treating Covid-19 after its Phase 3 clinical trials showed promising results. The drug reduced the duration for supplemental oxygen to 56 hours from 84 hours in moderate Covid-19 patients, Zydus Cadila said in a statement. “With …
So far, Thymosin @-1 injection 1.6 mg has been used to treat chronic Hepatitis B New Delhi: The Subject Expert Committee at the Central Drugs Standard Control Organisation has recommended that the country’s top drug regulator grant permission for phase 3 clinical trial using Thymosin @-1 injection 1.6 mg on moderate to severe COVID-19 patients, said a senior health ministry …
New Delhi: The Subject Expert Committee at the Central Drugs Standard Control Organisation has recommended that the country's top drug regulator grant permission for phase 3 clinical trial using Thymosin @-1 injection 1.6 mg on moderate to severe COVID-19 patients, said a senior health ministry official on Wednesday. The senior government official said: "Domestic pharma giant Gufic Bioscience has submitted …
)
)
